Relief Therapeutics Holding SA (RLFTF)
1.39
-0.01
(-0.71%)
USD |
OTCM |
May 03, 16:00
Relief Therapeutics Debt to Equity Ratio: 0.0066 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.0066 |
| June 30, 2023 | 0.004 |
| December 31, 2022 | 0.0027 |
| June 30, 2022 | 0.0025 |
| December 31, 2021 | 0.0027 |
| June 30, 2021 | 0.0416 |
| December 31, 2020 | 0.00 |
| June 30, 2020 | 0.0719 |
| December 31, 2019 | 0.0673 |
| June 30, 2019 | 0.0358 |
| December 31, 2018 | 0.218 |
| June 30, 2018 | 0.2559 |
| December 31, 2017 | 0.015 |
| June 30, 2017 | 0.0399 |
| December 31, 2016 | 0.0395 |
| June 30, 2016 | 0.2057 |
| Date | Value |
|---|---|
| December 31, 2015 | 0.00 |
| June 30, 2015 | 0.1543 |
| December 31, 2014 | 0.1467 |
| June 30, 2014 | 0.4604 |
| December 31, 2013 | 0.4153 |
| June 30, 2013 | -0.9527 |
| December 31, 2012 | 0.6714 |
| June 30, 2012 | -1.244 |
| December 31, 2011 | 0.7292 |
| June 30, 2011 | 0.0659 |
| December 31, 2010 | 0.0075 |
| June 30, 2010 | 0.0043 |
| December 31, 2009 | 0.0058 |
| June 30, 2009 | 0.0071 |
| December 31, 2008 | 0.0075 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
0.0719
Maximum
Jun 2020
0.0235
Average
0.0053
Median
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | 0.00 |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 90.95M |
| Total Liabilities (Quarterly) | 28.77M |
| Shareholders Equity (Quarterly) | 62.18M |
| Current Ratio | 2.649 |
| Net Debt Paydown Yield | 0.01% |